Literature DB >> 28306371

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Heinz Ludwig1, Meletios A Dimopoulos2, Philippe Moreau3, Wee-Joo Chng4,5,6,7, Hartmut Goldschmidt8, Roman Hájek9, Thierry Facon10, Ludek Pour11, Ruben Niesvizky12, Albert Oriol13, Laura Rosiñol14, Aleksandr Suvorov15, Gianluca Gaidano16, Tomas Pika17, Katja Weisel18, Vesselina Goranova-Marinova19, Antonio Palumbo20, Heidi H Gillenwater21, Nehal Mohamed21, Sanjay Aggarwal21, Shibao Feng21, Douglas Joshua22.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28306371     DOI： 10.1080/10428194.2017.1298755

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

Review 1.  Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

Authors:  Adeela Mushtaq; Vikas Kapoor; Azka Latif; Ahmad Iftikhar; Umar Zahid; Ali McBride; Ivo Abraham; Irbaz Bin Riaz; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2018-03-02       Impact factor: 6.312

2.  Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.

Authors:  Thierry Facon; Ruben Niesvizky; Maria-Victoria Mateos; David Siegel; Cara Rosenbaum; Sara Bringhen; Katja Weisel; P Joy Ho; Heinz Ludwig; Shaji Kumar; Kenneth Wang; Mihaela Obreja; Zhao Yang; Zandra Klippel; Khalid Mezzi; Amanda Goldrick; Christina Tekle; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2020-11-10

3.  Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Authors:  Yuka Kawaji-Kanayama; Ayako Muramatsu; Nana Sasaki; Kazuho Shimura; Miki Kiyota; Shinichi Fuchida; Reiko Isa; Takahiro Fujino; Yayoi Matsumura-Kimoto; Taku Tsukamoto; Yoshiaki Chinen; Shinsuke Mizutani; Mitsushige Nakao; Hiroto Kaneko; Eri Kawata; Koichi Hirakawa; Ryoichi Takahashi; Chihiro Shimazaki; Hitoji Uchiyama; Nobuhiko Uoshima; Yuji Shimura; Tsutomu Kobayashi; Masafumi Taniwaki; Junya Kuroda
Journal:  Int J Hematol       Date:  2022-01-24       Impact factor: 2.490

Review 4.  Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Authors:  Ajai Chari; A Keith Stewart; Stuart D Russell; Philippe Moreau; Joerg Herrmann; Jose Banchs; Roman Hajek; John Groarke; Alexander R Lyon; George N Batty; Sunhee Ro; Mei Huang; Karim S Iskander; Daniel Lenihan
Journal:  Blood Adv       Date:  2018-07-10

Review 5.  Emerging drugs and combinations to treat multiple myeloma.

Authors:  Alessandra Larocca; Roberto Mina; Francesca Gay; Sara Bringhen; Mario Boccadoro
Journal:  Oncotarget       Date:  2017-07-15

6.  Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.

Authors:  Meletios A Dimopoulos; Ruben Niesvizky; Katja Weisel; David S Siegel; Roman Hajek; María-Victoria Mateos; Michele Cavo; Mei Huang; Anita Zahlten-Kumeli; Philippe Moreau
Journal:  Blood Cancer J       Date:  2020-03-09       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.